Healthcare providers (HCPs) are facing a digital deluge and successive studies reveal that most messaging gets lost in the flood. The torrent of ill-directed communication and ill-
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
